Jan. 15 at 4:48 PM
Boston Scientific agreed to acquire Penumbra in a
$14.5 billion cash-and-stock deal, valuing the medical device maker at
$374 per share. The transaction significantly expands Boston Scientific’s vascular medicine business by adding Penumbra’s portfolio of mechanical thrombectomy devices, which are used to treat serious cardiovascular conditions such as stroke, pulmonary embolism, deep vein aneurysms, and heart attacks.
Following the announcement, Penumbra shares surged about 12%, reflecting investor enthusiasm for the takeover premium, while Boston Scientific stock fell more than 4%, becoming the worst-performing stock in the S&P 500 during premarket trading. The reaction highlights near-term investor concerns about dilution and integration costs.
The deal, expected to close in 2026, is forecast to reduce Boston Scientific’s earnings by 6 to 8 cents per share in the first full year after completion.
$BSX $PEN $SPX